

Formulary Kit

FreeStyle Libre 3 system







Product images are for illustrative purposes only. Not actual patient data.

Abbott provides this information as a courtesy; it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors. Medicare coverage is available for FreeStyle Libre systems if their respective readers are used to review glucose data on some days every month. Medicare and other third party payor criteria apply.

The FreeStyle Libre 3 app and the FreeStyle Libre 3 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.

The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app.

The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.

Proprietary and confidential — do not distribute. © 2023 Abbott. ADC-48353 v5.0



October 2023

Dear Health Plan Administrator,

We are pleased to present Abbott's next-generation system, the FreeStyle Libre 3 system.

The FreeStyle Libre 3 system is a real-time continuous glucose monitoring (CGM) device with real-time alarms* indicated for use in people living with diabetes ages 4 and older.

The FreeStyle Libre 3 system provides the same real-time glucose alarms*, but also evolves the portfolio with new features, such as:

- Real-time glucose readings every minute to your members' smartphones[†] or readers[‡]
- Unsurpassed 14-day accuracy with a 7.9% overall MARD (Adults and Pediatrics)
- Easy to use^{§2}, one-piece sensor application, requiring no in-person training³
- The world's smallest, thinnest and most discreet sensor

This FreeStyle Libre 3 system Formulary Kit contains the following:

- Product information
- Clinical guidelines
- Clinical highlights
- Digital health tools
- Pricing information
- Prescribing information
- Resources

Please reach out to your Abbott account manager for more information about the FreeStyle Libre 3 system.

Best regards,
Jody Boeddeker
General Manager, Market Access

References: 1. FreeStyle Libre 3 User's Manual. 2. Haak, T. Diabetes Ther (2017): https://doi.org/10.1007/s13300-016-0223-6 3. Data on file, Abbott Diabetes Care.

The FreeStyle Libre 3 system is indicated for use in people with diabetes age 4 and older.

^{*} Notifications will only be received when alarms are turned on and the sensor is within 33 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 3 User's Manual for more information.

[†] The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app.

[‡] The FreeStyle Libre 3 app and the FreeStyle Libre 3 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.

[§] Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore the study data is applicable to both products.

II Among patient-applied sensors.



Table of Contents

| Product Information | Pages 4-5 |
|--|-----------|
| Product Comparison | Page 6 |
| Digital Health Tools | Page 7 |
| Clinical Guidelines for the Use of CGM: Highlights | Page 8 |
| Clinical Outcomes: Highlights | Page 9 |
| Pricing Information | Page 10 |
| Prescribing Information | Page 11 |
| Resources | Page 12 |
| Important Safety Information | Page 13 |



Product Information

System Components

The FreeStyle Libre 3 system helps to build a complete glycemic picture that enables patients, caregivers, and healthcare providers to make informed disease management and treatment decisions.

The FreeStyle Libre 3 sensor is easy to apply¹, using a 1-piece applicator, and easy to use*², requiring no in-person training¹.



FreeStyle Libre 3 sensor

The FreeStyle Libre 3 sensor is the smallest CGM sensor on the market, designed to be discreet¹ and provide patients with greater flexibility. The sensor provides glucose readings that can be streamed directly to your members' smartphone¹ or scanned with a reader‡. The sensor has 14-day wear and data storage, and simplified sensor application in the position of attachment. The sensor stores retrospective glucose data over the full 14-day wear period.



FreeStyle Libre 3 app[†]

The FreeStyle Libre 3 app is designed to be used by people living with diabetes. The app enables the user to carry out routine glucose monitoring using a compatible smartphone and the FreeStyle Libre 3 sensor. The FreeStyle Libre 3 app is designed to offer 3 optional alarms[§] (low glucose, high glucose, and signal loss) and 1 mandatory urgent low alarm (set at 55 mg/dL).







FreeStyle Libre 3 reader[‡]

The reader obtains glucose readings via streaming from the sensor and can issue glucose alarms§. It is handheld and lightweight, with a backlit color touchscreen. The reader can store approximately 90 days of glucose history and notes entered about activities, such as taking insulin, eating food, or exercising. This information can help patients understand how these activities affect their glucose. The reader also includes a built-in meter for blood glucose testing. To use the built-in meter, patients need the FreeStyle Precision Neo blood glucose test strips, control solution, a lancing device, and lancets. These items are not included in the reader kit and must be obtained separately from their FreeStyle Libre 3 system provider (pharmacy or mail-order supplier).

Product images are for illustrative purposes only. Not actual patient data.

Abbott provides this information as a courtesy; it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors. Medicare coverage is available for FreeStyle Libre systems if their respective readers are used to review glucose data on some days every month. Medicare and other third party payor criteria apply.

- * Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore the study data is applicable to both products.
- † The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app.
- ‡ The FreeStyle Libre 3 app and the FreeStyle Libre 3 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.
- § Notifications will only be received when alarms are turned on and the sensor is within 33 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 3 User's Manual for more information.

References: 1. Data on file, Abbott Diabetes Care. 2. Haak, T. Diabetes Ther (2017): https://doi.org/10.1007/s13300-016-0223-6



Product Information

Alarms*

The FreeStyle Libre 3 system provides real-time glucose alarms* with readings streaming every minute¹. The system is designed to offer 3 optional alarms (low glucose, high glucose, and signal loss) and 1 mandatory urgent low alarm (set at 55 mg/dL).



Optional, low glucose alarm:Notifies when glucose is BELOW a set level (60-100 mg/dL)



Optional, high glucose alarm: Notifies when glucose is ABOVE a set level (120-400 mg/dL)



Optional, signal loss alarm:
Notifies when sensor is not
communicating with smartphone or
reader[†] and that low or high glucose
alarms will not be received

The FreeStyle Libre 3 app[‡] has a mandatory Urgent Low Glucose Alarm that lets users know when their glucose value is below 55 mg/dL.

Accuracy¹

FreeStyle Libre 3 system accuracy to YSI (n=95)

| Patient population | Number of subjects | Total number of paired CGM- Reference | Percent within 20/20% Reference | MARD (%) |
|------------------------|--------------------|--|--|----------|
| Overall | 95 | 6836 | 93.2 | 7.9 |
| ≥ 18 years | 56 | 4768 | 94.7 | 7.6 |
| 6-17 years | 39 | 2068 | 89.7 | 8.7 |
| 4-5 years [§] | 5 | 72 | 88.9 | 10.1 |

Reference: 1. FreeStyle Libre 3 User's Manual.

^{*} Notifications will only be received when alarms are turned on and the sensor is within 33 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 3 User's Manual for more information.

[†] The FreeStyle Libre 3 app and the FreeStyle Libre 3 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.

[‡] The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app.

[§] Using BGM reference.



Product Comparison

FreeStyle Libre 2 system¹

FreeStyle Libre 3 system²





Glucose data transfer to reader/smartphone

Real-time glucose readings and real-time alarms*

Real-time glucose readings and real-time alarms[†]

Glucose viewing

Scan (to app[‡] or reader[§])

Stream (to app|| or reader#)

Sensor wear

14-day

14-day

Configuration

Sensor with app[‡] or reader[§]

Sensor with app or reader#



2-piece

1-piece

Applicator

Sensor size

4 and above

4 and above

Age

1.18" x 0.2"

(3)

0.83" x 0.11"





Product images are for illustrative purposes only. Not actual patient data.

Abbott provides this information as a courtesy; it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors. Medicare coverage is available for FreeStyle Libre systems if their respective readers are used to review glucose data on some days every month. Medicare and other third party payor criteria apply.

- * Notifications will only be received when alarms are turned on and the sensor is within 20 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 2 User's Manual for more information.
- † Notifications will only be received when alarms are turned on and the sensor is within 33 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 3 User's Manual for more information.
- ‡ The FreeStyle Libre 2 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app. Use of the FreeStyle Libre 2 app requires registration with LibreView.
- § The FreeStyle Libre 2 app and the FreeStyle Libre 2 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.
- II The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app.
- # The FreeStyle Libre 3 app and the FreeStyle Libre 3 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.

References: 1. FreeStyle Libre 2 User's Manual. 2. FreeStyle Libre 3 User's Manual.



Digital Health Tools



FreeStyle Libre 3 app* - for the patient

The FreeStyle Libre 3 app provides real-time glucose readings streamed every minute directly to your member's smartphone* so they can act faster and make timely diabetes treatment decisions.

With helpful reports, easy-to-read charts, and the ability to privately share user's glucose readings with up to 20 individuals from their care team, the FreeStyle Libre 3 app* helps users manage their diabetes daily.

The FreeStyle Libre 3 app is not compatible with the FreeStyle Libre 2 system.



LibreLinkUp app † — for the caregivers

The LibreLinkUp app is designed to be used by family, friends, and other caregivers of patients using the FreeStyle Libre 3 app. The LibreLinkUp app allows users to follow up to 20 different connections. LibreLinkUp users receive real-time glucose information (including a 12-hour graph) and can customize their own glucose alarms^{†‡§}.



LibreView desktop application — for the healthcare professional and the patient

LibreView is a secure*, cloud-based data management system. It is HIPAA compliant and allows data to be accessed at any time. Streamed glucose data is compiled into easy-to-read**1 reports, glucose patterns, and trends. LibreView is intended for use by both patients and healthcare professionals to assist people living with diabetes.

Product images are for illustrative purposes only. Not actual patient data.

Abbott provides this information as a courtesy; it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors. Medicare coverage is available for FreeStyle Libre systems if their respective readers are used to review glucose data on some days every month. Medicare and other third party payor criteria apply.

- * The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app.
- † The LibreLinkUp app is only compatible with certain mobile devices and operating systems. Please check http://www.librelinkup.com for more information about device compatibility before using the app. Use of the LibreLinkUp app requires registration with LibreView. LibreLinkUp is not intended to be used for dosing decisions. The user should follow instructions on the continuous glucose monitoring system. LibreLinkUp is not intended to replace self-monitoring practices as advised by a physician.
- ‡ The user's device must have internet connectivity for glucose data to automatically upload to LibreView and to transfer to connected LibreLinkUp app users.
- § Notifications will only be received when alarms are turned on and the sensor is within 33 feet unobstructed of the reading device. You must enable the appropriate settings on your smartphone to receive alarms and alerts, see the FreeStyle Libre 3 User's Manual for more information.
- Il The LibreView data management software is intended for use by both patients and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis and evaluation of historical glucose meter data to support effective diabetes management. The LibreView software is not intended to provide treatment decisions or to be used as a substitute for professional healthcare advice.
- # LibreView is ISO27001/27018/27701 certified and HITRUST CSF Certified.
- ** Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 system has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore the study data is applicable to both products.

Reference: 1. Unger, J. *Postgraduate Medicine* (2020): https://doi.org/10.1080/00325481.2020.1744393



Clinical Guidelines for the Use of CGM: Highlights

Several clinical organizations, including the ADA and AACE, have published guidelines for the use of CGM in the management of diabetes¹⁻³.

American Diabetes Association (ADA) American Diabetes Association. American Diabetes Association.



The ADA published diabetes treatment guidelines as part of the 2023 Standards of Care in Diabetes, making the following clinical and access recommendations for CGM1:

- CGM is recommended for all insulin-using patients, choice of the device should be made on the individual's circumstances, preferences, and needs
- CGM can be a useful tool for guiding medical nutrition therapy, physical activity, preventing hypoglycemia, and adjusting medications
- CGM users should have uninterrupted access through third-party payers

American Association of Clinical Endocrinology (AACE) AACE.

The AACE published recommendations in 20222 and 20233 regarding the use of CGM systems in the management of people with diabetes. The following recommendations were highlighted with respect to continuous glucose monitoring^{2,3}:

- Lifestyle intervention and ongoing glucose monitoring with CGM preferred²
- CGM is recommended for all insulin-using patients and those at risk for hypoglycemia²
- CGM is highly recommended for all patients to reach glycemic goals safely³
- CGM metrics can be used as a surrogate to HbA1c³
- isCGM could be helpful to newly diagnosed T2D patients and those at low risk for hypoglycemia³

CGM Metrics: Recommendations from ADA and AACE





- Two metrics, %TIR (Time in Range) and %TBR (Time Below Range), should be used as a starting point for the assessment of quality of glycemic control and as the basis for therapy adjustment, with emphasis on reducing %TBR when the percentages of CGM values falling below 54 mg/dL or 70 mg/dL are close to or exceed targets²
- Due to the limitations of HbA1c, clinicians should exercise judgement when using HbA1c as the sole basis for assessing glycemic control; recommend the inclusion of CGM metrics such as Glucose Variability (GV) and Time in Range (TIR)1

References: 1. ADA. Standards of Care in Diabetes—2023. Diabetes Care (2023) https://doi.org/10.2337/dc23-S007 2. AACE Clinical Practice Guidelines, Volume 28, Issue 10, P923-1049, (2022): https://doi.org/10.1016/j.eprac.2022.08.002 3. AACE Clinical Practice Guidelines, Volume 28, Issue 5, 305-340, (2023): https://doi.org/10.1016/j.eprac.2023.02.001



Clinical Outcomes: Highlights

Use of the FreeStyle Libre family of personal CGMs is associated with:

Reduced HbA1c across multiple groups of patients*1-7

Increased Time in Range (TIR)*2,3,8,9

Reduced number of hypoglycemic events*8,10

Reduced resource utilization*11-13

40.42%-0.59%

HbA1c reduction observed among patients with T1D/T2D in a meta-analysis*†1

♦ 0.4-0.5%

HbA1c reduction among children and teenagers (4-17 years) with T1D*2,3

↓0.4%

HbA1c reduction among patients with T1D*4

↓ 0.52%-1.6%

reduction in HbA1c
among people with
T2D*5-7

↑ 1-2.17 hrs/day

increased TIR observed among patients with T1D*2,3,8

↑ 2.36 hrs/day

increased TIR observed among patients with T2D*9 **₹26%**

reduction in number of hypoglycemic events among patients with T1D*8

√28%

reduction in number of hypoglycemic events among patients with T2D on intensive insulin regimens*10 **483%**

reduction in number of diabetes-related hospital admissions among patients with T1D or T2D*11

√61%

reduction in acute diabetes events among patients with T2D on intensive insulin regimens**¹²

√32%

reduction in all-cause hospitalization rates among patients with T2D on intensive insulin regimens***12

↓37%

reduction in acute diabetes event rates among patients with T2D on basal insulin*‡13

425%

reduction in acute diabetes event rates among patients with T2D on non-insulin therapies***13

^{*} Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore, the study data is applicable to both products.

[†] A meta-analysis of 75 real- world observational studies) on the impact of flash continuous glucose monitoring on glycemic control as measured by HbA1c.

[‡] Acute diabetes events include hospitalizations or outpatient emergency room visits associated with hyper- or hypoglycemic events

References: 1. Evans, M. Diabetes Ther (2022): https://doi.org/10.1007/s13300-022-01253-9 2. Campbell, F. Pediatr Diabetes (2018): https://doi.org/10.1111/pedi.12735 3. Leelarathna L, et al. N Engl J Med (2022): https://doi.org/10.1007/s13300-019-00741-9 6. Wright, E. Diabetes Spectr (2021): https://doi.org/10.1007/s13300-019-00741-9 6. Wright, E. Diabetes Spectr (2021): https://doi.org/10.2337/ds20-0069 7. Eeg-Olofsson K. Diabetes (2020): https://doi.org/10.2337/ds20-0069 7. Eeg-Olofsson K. Diabetes (2020): https://doi.org/10.2037/ds20-0069 7. Eeg-Olofsson K. Diabetes (2020): https://doi.org/10.1016/s0140-6736(16)31535-5 9. Wada E, et al. https://doi.org/10.1136/bmjdrc-2019-001115 10. Haak, T. Diabetes Ther (2017): https://doi.org/10.1136/bmjdrc-2019-001115 10. Haak, T. Diabetes Ther (2017): https://doi.org/10.1136/bmjdrc-2019-000809 12. Bergenstal, R. J Endocr Soc (2021): https://doi.org/10.1136/bmjdrc-2019-000809 12. Bergenstal, R. J Endocr Soc (2021): https://doi.org/10.1136/bmjdrc-2019-000809 12. Bergenstal, R. J Endocr Soc (2021): https://doi.org/10.1136/bmjdrc-2019-000809 12. Bergenstal, R. J Endocr Soc (2021): https://doi.org/10.1136/bmjdrc-2019-000809 12. Bergenstal, R. J Endocr Soc (2021): <a href="https://doi.or



Pricing Information

FreeStyle Libre 3 system







| | FreeStyle Libre 3 Reader Kit | FreeStyle Libre 3 Sensor Kit |
|---------------------|-------------------------------|------------------------------|
| SKU# | 72079-01 | 72081-01 |
| Package Size | 1 Reader | 1 sensor |
| Unit Price | \$70.00 | \$64.22 |
| NRC | 57599-0820-00 | 57599-0818-00 |
| UPC | 357599820008 | 357599818005 |
| Unit Pkg. Weight | 0.865 lb | 0.13 lb |
| Storage Temperature | -4°F to 140°F (-20°C to 60°C) | 36°F to 82°F (3°C to 28°C) |
| Storage Humidity | 10% to 90% | 10% to 90% |
| Contains Battery | Yes | Yes |

Product images are for illustrative purposes only. Not actual patient data.


Abbott provides this information as a courtesy; it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors. Medicare coverage is available for FreeStyle Libre systems if their respective readers are used to review glucose data on some days every month. Medicare and other third party payor criteria apply.



Prescribing Information

FreeStyle Libre 3 system







How to get the FreeStyle Libre 3 app*

Once your member receives their prescription for the FreeStyle Libre 3 system, they can download the app to their compatible smartphone at no cost.







Product images are for illustrative purposes only. Not actual patient data.

Abbott provides this information as a courtesy; it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors. Medicare coverage is available for FreeStyle Libre systems if their respective readers are used to review glucose data on some days every month. Medicare and other third party payor criteria apply.

The FreeStyle Libre 3 app and the FreeStyle Libre 3 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.

* The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app.



Resources

Sign up to learn more: Payer.FreeStyle.Abbott

- Support for Payers
- Latest Clinical Evidence
- Connect with an Account Manager

Website for providers: FreeStyleProvider.Abbott

- Support for Providers
- How to Prescribe
- Practice Resources

Website for members: FreeStyle.Abbott

- Support for Members
- Patient Stories
- Getting Started and MyFreeStyle Program



Important Safety Information

FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use FreeStyle Libre 2 or FreeStyle Libre 3 systems as instructed in labeling may result in missing a severe low or high glucose event or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or https://www.FreeStyle.abbott/us-en/safety-information.html for safety info.

| The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks |
|---|
| are the property of their respective owners. |
| |









life. to the fullest.®

Abbott

Product images are for illustrative purposes only. Not actual patient data.

Abbott provides this information as a courtesy, it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors. Medicare coverage is available for FreeStyle Libre systems if their respective readers are used to review glucose data on some days every month. Medicare and other third party payor criteria apply.

The FreeStyle Libre 3 system is indicated for use in people with diabetes age 4 and older.

The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app.

The FreeStyle Libre 3 app and the FreeStyle Libre 3 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.

Important Safety Information on page 13.